يعرض 1 - 9 نتائج من 9 نتيجة بحث عن '"Lara Carmen Iglesias Docampo"', وقت الاستعلام: 0.83s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer

    المؤلفون: Ramon Yarza, Mateo Bover, Maria Teresa Agulló-Ortuño, Lara Carmen Iglesias-Docampo

    المصدر: Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-18 (2021)

    مصطلحات موضوعية: Nasopharyngeal carcinoma, Proteasome, Bortezomib, Immunotherapy, Epstein Barr virus, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    Relation: https://doaj.org/toc/1756-9966

    URL الوصول: https://doaj.org/article/69d30d5cc6f344f0862b54b6d050f096

    Find this article in full text from Springer Verlag. Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer : Subgroup Analysis of CheckMate 141

    المؤلفون: Maura L Gillison, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin J Harrington, Stefan Kasper, Everett E Vokes, Caroline Even, Francis Worden, Nabil F Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Vijayvel Jayaprakash, Li Wei, Robert L Ferris

    مصطلحات موضوعية: Cancer Research, Nivolumab, Oncology, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Medizin, Humans, Neoplasm Recurrence, Local, Platinum

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d8adb6da303b0dd011608467144cda2
    https://www.ncbi.nlm.nih.gov/pubmed/35641218

    أضف إلى المفضلة
  3. 3
    CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

    المؤلفون: Jérôme Fayette, George R. Blumenschein, Joël Guigay, Everett E. Vokes, Tamara Rordorf, Caroline Even, Nabil F. Saba, Lara Carmen Iglesias Docampo, Manish Monga, Robert L. Ferris, Robert I. Haddad, Kevin J. Harrington, Lisa Licitra, Naomi Kiyota, Li Li, A. Dimitrios Colevas, Maura L. Gillison, Stefan Kasper, Makoto Tahara, Francis P. Worden, Mark Lynch

    المساهمون: University of Zurich, Gillison, Maura L

    المصدر: The Oncologist. 23:1079-1082

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Medizin, Checkmate, 610 Medicine & health, Subgroup analysis, law.invention, Targeted therapy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Humans, 1306 Cancer Research, Chemotherapy, business.industry, Head and neck cancer, medicine.disease, stomatognathic diseases, Nivolumab, 030104 developmental biology, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, 10032 Clinic for Oncology and Hematology, 2730 Oncology, Neoplasm Recurrence, Local, Brief Communications, business, Adjuvant

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::befcb7cf1c25cba555a2d10d6f3f9c50
    https://doi.org/10.1634/theoncologist.2017-0674

    View record at Wiley
    أضف إلى المفضلة
  4. 4
    Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

    المؤلفون: Vijayvel Jayaprakash, Lisa Licitra, Nabil F. Saba, Jérôme Fayette, Joël Guigay, Naomi Kiyota, Robert L. Ferris, Kevin J. Harrington, Stefan Kasper, Li Li, Francis P. Worden, Caroline Even, Robert I. Haddad, Makoto Tahara, Maura L. Gillison, Lara Carmen Iglesias Docampo, Mark Lynch, Tamara Rordorf, Everett E. Vokes, George R. Blumenschein, A. Dimitrios Colevas

    المساهمون: University of Zurich, Ferris, Robert L

    المصدر: Oral oncology. 81

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, 610 Medicine & health, B7-H1 Antigen, Article, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Internal medicine, Clinical endpoint, medicine, Humans, 1306 Cancer Research, Neoplasm Metastasis, Head and neck, Survival analysis, business.industry, 3504 Oral Surgery, Squamous Cell Carcinoma of Head and Neck, Hazard ratio, Immunotherapy, Survival Analysis, 030104 developmental biology, Nivolumab, Tumor progression, 030220 oncology & carcinogenesis, 10032 Clinic for Oncology and Hematology, 2730 Oncology, Oral Surgery, Neoplasm Recurrence, Local, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f87f2559448dced407c7d4a74eabdbf4
    https://pubmed.ncbi.nlm.nih.gov/29884413

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  5. 5
    Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

    المؤلفون: Joachim von Pawel, Luis Paz-Ares, Ian Taylor, Hui Zhang, Pasi A. Jänne, Jaafar Bennouna, Zelanna Goldberg, Lara Carmen Iglesias Docampo, Jim P. Doherty, Cecile B. Mather, Mikhail Shtivelband, Tony Mok, Jane Q. Liang, Kenneth J. O'Byrne, Suresh S. Ramalingam, Joe O'Connell, Adam Pluzanski, Michael Boyer

    المصدر: The Lancet Oncology. 15:1369-1378

    مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, Phases of clinical research, medicine.disease_cause, Disease-Free Survival, Proto-Oncogene Proteins p21(ras), Erlotinib Hydrochloride, chemistry.chemical_compound, Double-Blind Method, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins, Internal medicine, medicine, Humans, Lung cancer, Protein Kinase Inhibitors, Aged, Neoplasm Staging, Quinazolinones, EGFR inhibitors, Performance status, business.industry, Hazard ratio, Middle Aged, medicine.disease, Dacomitinib, Surgery, ErbB Receptors, chemistry, Quinazolines, ras Proteins, Female, KRAS, Erlotinib, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba8eaff71b161868d911659dedebf47
    https://doi.org/10.1016/s1470-2045(14)70452-8

    View record from ScienceDirect Find this article in full text from ProQuest Full Text via ClinicalKey
    أضف إلى المفضلة
  6. 6
    Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    المؤلفون: Justin Kopit, George R. Blumenschein, Caroline Even, James W. Shaw, A. Dimitrios Colevas, Naomi Kiyota, Kevin J. Harrington, Joël Guigay, Jérôme Fayette, Robert L. Ferris, Everett E. Vokes, Lisa Licitra, Nabil F. Saba, Makoto Tahara, Mark Lynch, Tamara Rordorf, Lara Carmen Iglesias Docampo, William J. Geese, Stefan Kasper, Francis P. Worden, Robert I. Haddad, Maura L. Gillison, Manish Monga

    مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, medicine.medical_treatment, Medizin, Antineoplastic Agents, B7-H1 Antigen, Article, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Carcinoma, Clinical endpoint, Medicine, Humans, Survival analysis, Aged, Aged, 80 and over, Chemotherapy, Cetuximab, business.industry, Antibodies, Monoclonal, General Medicine, medicine.disease, Survival Analysis, 030104 developmental biology, Nivolumab, Docetaxel, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, Quality of Life, Carcinoma, Squamous Cell, Female, Neoplasm Recurrence, Local, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37038f077698b3441478a42ea98a55cd
    https://www.ncbi.nlm.nih.gov/pubmed/27718784

    أضف إلى المفضلة
  7. 7
    Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141

    المؤلفون: Nabil F. Saba, Li Li, Kevin J. Harrington, Vijayvel Jayaprakash, Stefan Kasper, Everett E. Vokes, Jérôme Fayette, Francis P. Worden, Lisa Licitra, Robert L. Ferris, A. Dimitrios Colevas, Lara Carmen Iglesias Docampo, Caroline Even, Makoto Tahara, Joël Guigay, Tamara Rordorf, Naomi Kiyota, Robert I. Haddad, Maura L. Gillison, Mark Lynch, George R. Blumenschein

    المصدر: Cancer Research. 78:CT116-CT116

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, education.field_of_study, biology, Cetuximab, business.industry, Population, Cancer, medicine.disease, Docetaxel, Internal medicine, PD-L1, medicine, biology.protein, Basal cell, Nivolumab, business, Head and neck, education, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::f37c5665f7454a800411f6bceb6ace7b
    https://doi.org/10.1158/1538-7445.am2018-ct116

    أضف إلى المفضلة
  8. 8
    Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy

    المؤلفون: Justin Kopit, Lisa Licitra, Mark Lynch, Joël Guigay, A. Dimitrios Colevas, Jérôme Fayette, Tamara Rordorf, Makoto Tahara, Nabil F. Saba, Lara Carmen Iglesias Docampo, Kevin J. Harrington, Maura L. Gillison, Robert I. Haddad, Stefan Kasper, Naomi Kiyota, Francis P. Worden, George R. Blumenschein, Robert L. Ferris, Caroline Even, Everett E. Vokes

    المصدر: Journal of Clinical Oncology. 35:6019-6019

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, education.field_of_study, Cetuximab, business.industry, Proportional hazards model, Population, Hazard ratio, Surgery, 03 medical and health sciences, 0302 clinical medicine, Docetaxel, Tolerability, 030220 oncology & carcinogenesis, Internal medicine, medicine, Clinical endpoint, Nivolumab, 030223 otorhinolaryngology, education, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::3b12090e358438cd014dedc0d6d9ac31
    https://doi.org/10.1200/jco.2017.35.15_suppl.6019

    أضف إلى المفضلة
  9. 9
    Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141

    المؤلفون: Everett E. Vokes, Lisa Licitra, Stefan Kasper, Caroline Even, Mark Schactman, Justin Kopit, Francis P. Worden, Joël Guigay, Robert L. Ferris, Kevin J. Harrington, Makoto Tahara, Nabil F. Saba, Lara Carmen Iglesias Docampo, William J. Geese, Mark Lynch, Tamara Rordorf, George R. Blumenschein, Maura L. Gillison, A. Dimitrios Colevas, James W. Shaw, Naomi Kiyota, Robert I. Haddad, Jérôme Fayette, Manish Monga

    المصدر: Cancer Research. 76:CT099-CT099

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, Cetuximab, business.industry, medicine.medical_treatment, Phases of clinical research, medicine.disease, Interim analysis, Head and neck squamous-cell carcinoma, Loading dose, Surgery, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Docetaxel, 030220 oncology & carcinogenesis, Internal medicine, medicine, Nivolumab, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::16e25b0fb306efe58dbada8e34f55f84
    https://doi.org/10.1158/1538-7445.am2016-ct099

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء